More Frequent Haemodialysis Improved Outcomes: The Wish Comes True at Home

This satellite symposium took place on 4th June 2017, as part of the 54th European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) congress in Madrid, Spain

Chairpersons: Maria Auxiliadora Bajo,1 Natalie Borman2
Speakers: Sunita Nair,3 Eric Goffin,4 Matthew Herbert,5 Kay Herbert5

1. Universitario La Paz, Madrid, Spain
2. Wessex Renal and Transplantation Unit, Portsmouth, Hampshire, UK
3. Shrewsbury and Telford NHS Trust, Shrewsbury, Shropshire, UK
4. Cliniques Universitaires Saint Luc – UCL, Brussels, Belgium
5. Patient representative, Waterlooville, Hampshire, UK

Disclosure: Dr Borman: Chair of the European medical board for NxStage and a paid speaker by NxStage. However, the clinical experience that is reflected in the manuscript and talks is from clinical practice at Wessex Kidney Centre, Portsmouth, UK. Dr Bajo is a paid speaker on behalf of NxStage and is also a member of the NxStage European Medical Board collecting the KIHDNEy cohort data. Dr Nair is a paid speaker on behalf of NxStage and is also a member of the NxStage European Medical Board collecting the KIHDNEy cohort data; Prof Goffin: Nothing to disclose; Mr and Mrs Herbert: Nothing to disclose.
Acknowledgements: Writing assistance was provided by Dr Blair Hesp, ApotheCom.
Support: The publication of this article was funded by NxStage. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily NxStage.
Important Information: All forms of haemodialysis, including treatments performed in-centre and at home, involve some risks. In addition, there are certain risks unique to treatment in the home environment. Patients differ and not everyone will experience the reported benefits of more frequent home haemodialysis. Talk to your doctor to see if more frequent home haemodialysis with NxStage® System One™ is right for you. Certain risks associated with haemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping.
Citation: EMJ Nephrol. 2017;5[1]:36-42.

Meeting Summary

The symposium reviewed the challenges in providing dialysis to patients with kidney disease and outlined data supporting the effectiveness of home haemodialysis for improving clinical outcomes and patient quality of life. Prof Maria Auxiliadora Bajo opened the symposium by introducing the NxStage® System One™ for home-based dialysis. Dr Natalie Borman discussed the growing global burden of dialysis treatments and the ability of new technologies, such as the NxStage System One, to meet this need. Dr Sunita Nair then reviewed outcomes for patients using home-based dialysis in the Knowledge to Improve Home Dialysis Network in Europe (KIHDNEy) cohort. Prof Eric Goffin outlined the need to manage phosphorus levels in patients undergoing dialysis and compared phosphorus measures in patients undergoing different dialysis modalities. Matthew Herbert and his wife Kay then described their personal experience of using home-based dialysis and the impact this has had on their quality of life.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Download (PDF, 125KB)

Comments are closed.